Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amivantamab (Primary) ; Atezolizumab (Primary) ; Avelumab (Primary) ; Cetuximab (Primary) ; FT 536 (Primary) ; Interleukin-2 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Trastuzumab (Primary) ; Antineoplastics; Cyclophosphamide; Fludarabine
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions
  • Sponsors Fate Therapeutics

    • Most Recent Events

    • 19 Sep 2023 Status changed from active, no longer recruiting to discontinued.
    • 28 Apr 2023 Status changed from recruiting to active, no longer recruiting.
    • 03 Nov 2022 According to a Fate Therapeutics media release, currently, enrollment is ongoing in the second three-dose escalation cohort (300 million cells per dose). The Company has now initiated enrollment of the combination regimen.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top